midazolam ๐Ÿถ Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definitionDrug idCAS RN
diazepam derivatives 1802 59467-70-8

Description:

MoleculeDescription

Molfile Inchi Smiles

Synonyms:

  • buccolam
  • midazolam
  • mezolam
  • midazolam hydrochloride
  • midazolam HCl
A short-acting hypnotic-sedative drug with anxiolytic and amnestic properties. It is used in dentistry, cardiac surgery, endoscopic procedures, as preanesthetic medication, and as an adjunct to local anesthesia. The short duration and cardiorespiratory stability makes it useful in poor-risk, elderly, and cardiac patients. It is water-soluble at pH less than 4 and lipid-soluble at physiological pH.
  • Molecular weight: 325.77
  • Formula: C18H13ClFN3
  • CLOGP: 3.42
  • LIPINSKI: 0
  • HAC: 3
  • HDO: 0
  • TPSA: 30.18
  • ALOGS: -4.52
  • ROTB: 1

  • Status: OFP

  • Legend:
    OFP - off patent
    OFM - off market
    ONP - on patent

Drug dosage:

DoseUnitRoute
5 mg N
15 mg O
15 mg P
10 mg SL

ADMET properties:

PropertyValueReference
BDDCS (Biopharmaceutical Drug Disposition Classification System) 1 Benet LZ, Broccatelli F, Oprea TI
S (Water solubility) 10.30 mg/mL Benet LZ, Broccatelli F, Oprea TI
EoM (Fraction excreted unchanged in urine) 5.60 % Benet LZ, Broccatelli F, Oprea TI
MRTD (Maximum Recommended Therapeutic Daily Dose) 0.26 ยตM/kg/day Contrera JF, Matthews EJ, Kruhlak NL, Benz RD
BA (Bioavailability) 44 % Kim MT, Sedykh A, Chakravarti SK, Saiakhov RD, Zhu H
Vd (Volume of distribution) 1.10 L/kg Lombardo F, Berellini G, Obach RS
CL (Clearance) 5.30 mL/min/kg Lombardo F, Berellini G, Obach RS
fu (Fraction unbound in plasma) 0.02 % Lombardo F, Berellini G, Obach RS
t_half (Half-life) 3.10 hours Lombardo F, Berellini G, Obach RS

Approvals:

DateAgencyCompanyOrphan
Dec. 20, 1985 FDA
Sept. 25, 2020 PMDA TAKEDA PHARMACEUTICAL COMPANY LIMITED

FDA Adverse Event Reporting System (Female)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Status epilepticus 271.44 14.44 130 23401 13276 50568317
Hypotension 237.44 14.44 406 23125 235063 50346530
Multiple-drug resistance 214.15 14.44 74 23457 3240 50578353
Cardiac arrest 213.09 14.44 227 23304 83424 50498169
Serotonin syndrome 204.49 14.44 133 23398 24580 50557013
Anaphylactic reaction 190.21 14.44 175 23356 53880 50527713
Propofol infusion syndrome 149.24 14.44 40 23491 726 50580867
Drug interaction 137.48 14.44 293 23238 199328 50382265
Fatigue 128.90 14.44 86 23445 707515 49874078
Diabetes insipidus 115.80 14.44 43 23488 2321 50579272
Tachycardia 114.94 14.44 183 23348 99580 50482013
Respiratory acidosis 111.58 14.44 55 23476 5973 50575620
Labile blood pressure 103.13 14.44 36 23495 1624 50579969
Metabolic acidosis 99.85 14.44 106 23425 38719 50542874
Multiple organ dysfunction syndrome 99.74 14.44 120 23411 50217 50531376
Drug ineffective 99.25 14.44 684 22847 818649 49762944
Seizure 97.68 14.44 187 23344 117687 50463906
Joint swelling 96.91 14.44 4 23527 245282 50336311
Generalised tonic-clonic seizure 96.02 14.44 87 23444 26223 50555370
Encephalopathy 95.61 14.44 97 23434 33614 50547979
Myoglobin urine present 93.44 14.44 24 23507 366 50581227
Drug ineffective for unapproved indication 88.93 14.44 76 23455 21205 50560388
Circulatory collapse 88.87 14.44 74 23457 19926 50561667
Agitation 86.31 14.44 115 23416 53269 50528324
Anaphylactic shock 86.31 14.44 73 23458 20082 50561511
Unwanted awareness during anaesthesia 85.52 14.44 21 23510 264 50581329
Alopecia 84.93 14.44 8 23523 245039 50336554
Toxic encephalopathy 80.84 14.44 43 23488 5472 50576121
Intra-abdominal pressure increased 80.46 14.44 19 23512 200 50581393
Pain 80.17 14.44 91 23440 578812 50002781
Mitochondrial DNA mutation 77.96 14.44 19 23512 231 50581362
Myoclonus 75.89 14.44 59 23472 14411 50567182
Renal ischaemia 75.04 14.44 22 23509 560 50581033
Abdominal discomfort 74.15 14.44 10 23521 231631 50349962
Bradycardia 73.89 14.44 118 23413 64308 50517285
Shock 70.90 14.44 66 23465 20584 50561009
Oxygen saturation abnormal 69.65 14.44 31 23500 2671 50578922
Swelling 68.43 14.44 7 23524 200865 50380728
Pneumatosis 67.69 14.44 19 23512 412 50581181
Intestinal ischaemia 64.93 14.44 40 23491 6717 50574876
Delirium 64.38 14.44 84 23447 38108 50543485
PCO2 increased 64.20 14.44 23 23508 1120 50580473
Ventricular hypokinesia 63.94 14.44 33 23498 3947 50577646
PO2 increased 63.52 14.44 21 23510 801 50580792
Partial seizures 63.15 14.44 35 23496 4830 50576763
Fall 63.03 14.44 39 23492 334893 50246700
Arthralgia 62.80 14.44 67 23464 438635 50142958
Unresponsive to stimuli 62.30 14.44 74 23457 30535 50551058
Systemic inflammatory response syndrome 61.94 14.44 35 23496 5014 50576579
Hepatic ischaemia 61.33 14.44 19 23512 586 50581007
Arthropathy 60.94 14.44 3 23528 157903 50423690
Off label use 60.55 14.44 402 23129 474024 50107569
Nausea 60.54 14.44 151 23380 705247 49876346
Drug intolerance 60.26 14.44 14 23517 219090 50362503
Blood pH decreased 59.57 14.44 27 23504 2428 50579165
Pulseless electrical activity 59.46 14.44 38 23493 6803 50574790
Electrocardiogram QRS complex prolonged 57.45 14.44 34 23497 5310 50576283
Delayed recovery from anaesthesia 57.34 14.44 19 23512 730 50580863
Necrosis ischaemic 56.14 14.44 19 23512 780 50580813
Respiratory failure 55.98 14.44 128 23403 91053 50490540
Peripheral swelling 54.98 14.44 14 23517 205922 50375671
Anaesthetic complication 54.94 14.44 23 23508 1707 50579886
Anticholinergic syndrome 54.12 14.44 23 23508 1772 50579821
Malaise 54.10 14.44 46 23485 335486 50246107
Apnoea 53.96 14.44 36 23495 6930 50574663
Pain in extremity 53.82 14.44 30 23501 272835 50308758
Diarrhoea 53.58 14.44 122 23409 588354 49993239
Foetal death 53.29 14.44 38 23493 8142 50573451
Systemic lupus erythematosus 53.23 14.44 3 23528 140619 50440974
Hepatic failure 52.85 14.44 70 23461 32213 50549380
Perforation 52.65 14.44 19 23512 945 50580648
Cardiogenic shock 51.90 14.44 49 23482 15550 50566043
Neuromuscular block prolonged 51.60 14.44 16 23515 495 50581098
Acute respiratory distress syndrome 51.40 14.44 56 23475 21043 50560550
Respiratory depression 50.39 14.44 43 23488 11967 50569626
Oropharyngeal oedema 48.14 14.44 13 23518 243 50581350
Muscle relaxant therapy 47.94 14.44 12 23519 164 50581429
Blood creatine phosphokinase increased 47.59 14.44 60 23471 26307 50555286
Renal impairment 47.31 14.44 107 23424 75554 50506039
Epileptic aura 47.17 14.44 10 23521 61 50581532
Ventricular extrasystoles 46.89 14.44 39 23492 10477 50571116
Nasopharyngitis 46.24 14.44 16 23515 192911 50388682
Headache 46.07 14.44 105 23426 506430 50075163
Electrocardiogram ST segment depression 45.80 14.44 23 23508 2597 50578996
Epilepsy 45.31 14.44 53 23478 21514 50560079
Oxygen saturation decreased 45.14 14.44 103 23428 73145 50508448
Electrocardiogram ST segment elevation 45.12 14.44 25 23506 3448 50578145
Blood bicarbonate decreased 44.95 14.44 23 23508 2702 50578891
Anaesthetic complication pulmonary 44.65 14.44 9 23522 41 50581552
Infusion related reaction 44.35 14.44 12 23519 169545 50412048
Hypoxia 43.38 14.44 82 23449 51041 50530552
Anorectal ulcer 43.17 14.44 9 23522 50 50581543
Non-consummation 42.72 14.44 9 23522 53 50581540
Mydriasis 42.45 14.44 37 23494 10590 50571003
Electroencephalogram abnormal 42.23 14.44 24 23507 3475 50578118
Cardiotoxicity 42.03 14.44 31 23500 6996 50574597
Female genital tract fistula 41.19 14.44 24 23507 3642 50577951
Product dose omission issue 41.13 14.44 17 23514 183821 50397772
Diabetic macroangiopathy 41.00 14.44 10 23521 122 50581471
Intestinal infarction 40.90 14.44 16 23515 996 50580597
Blood gases abnormal 40.24 14.44 14 23517 625 50580968
Toxicity to various agents 40.05 14.44 200 23331 212299 50369294
Brain oedema 39.52 14.44 38 23493 12332 50569261
Amylase increased 39.52 14.44 27 23504 5403 50576190
Colitis 39.34 14.44 67 23464 38462 50543131
Disseminated intravascular coagulation 39.18 14.44 44 23487 17091 50564502
Bronchospasm 38.95 14.44 41 23490 14813 50566780
Ultrasound ovary abnormal 38.80 14.44 9 23522 87 50581506
Weight increased 38.64 14.44 23 23508 201868 50379725
Hepatorenal syndrome 38.63 14.44 18 23513 1725 50579868
Pseudopolyp 38.62 14.44 11 23520 252 50581341
Altered state of consciousness 38.18 14.44 49 23482 21861 50559732
Contraindicated product administered 38.10 14.44 11 23520 148947 50432646
Upper airway obstruction 37.81 14.44 13 23518 560 50581033
Sinusitis 37.78 14.44 16 23515 170542 50411051
Unmasking of previously unidentified disease 37.55 14.44 14 23517 764 50580829
Gene mutation 37.37 14.44 16 23515 1255 50580338
Airway peak pressure increased 37.37 14.44 11 23520 284 50581309
Stress cardiomyopathy 36.73 14.44 30 23501 7857 50573736
Blood lactic acid increased 36.51 14.44 26 23505 5559 50576034
Discomfort 36.31 14.44 4 23527 108376 50473217
Troponin increased 35.98 14.44 30 23501 8088 50573505
Systolic dysfunction 35.12 14.44 16 23515 1456 50580137
Left ventricular dysfunction 34.94 14.44 33 23498 10473 50571120
Acid base balance abnormal 34.78 14.44 10 23521 237 50581356
Sinus bradycardia 33.88 14.44 36 23495 13147 50568446
Laryngeal stenosis 33.62 14.44 13 23518 784 50580809
Anaesthetic complication neurological 32.99 14.44 9 23522 175 50581418
Acute coronary syndrome 32.24 14.44 30 23501 9344 50572249
Haemodynamic instability 32.18 14.44 28 23503 7996 50573597
Encephalitis autoimmune 31.04 14.44 14 23517 1244 50580349
Proctitis 31.01 14.44 16 23515 1912 50579681
Gastrointestinal scarring 30.77 14.44 9 23522 227 50581366
Hyperammonaemic encephalopathy 30.47 14.44 16 23515 1983 50579610
Hepatocellular injury 30.38 14.44 48 23483 25899 50555694
Weight decreased 30.24 14.44 35 23496 221210 50360383
Drug-induced liver injury 30.20 14.44 50 23481 28045 50553548
Vaginal flatulence 30.19 14.44 9 23522 243 50581350
Product use in unapproved indication 30.09 14.44 120 23411 115699 50465894
Sinus tachycardia 29.98 14.44 43 23488 21311 50560282
Bulimia nervosa 29.86 14.44 10 23521 397 50581196
Tachyphylaxis 29.78 14.44 9 23522 255 50581338
Dizziness 29.67 14.44 74 23457 346295 50235298
Arthritis 29.56 14.44 3 23528 86718 50494875
Hypernatraemia 29.35 14.44 24 23507 6297 50575296
Drug resistance 29.28 14.44 40 23491 18949 50562644
Macroglossia 29.04 14.44 11 23520 627 50580966
Restlessness 28.69 14.44 46 23485 25127 50556466
Paradoxical drug reaction 28.61 14.44 19 23512 3628 50577965
Procedural vomiting 28.54 14.44 10 23521 456 50581137
Musculoskeletal stiffness 28.53 14.44 12 23519 128469 50453124
Lower respiratory tract infection 28.40 14.44 5 23526 95196 50486397
Gastrointestinal mucosa hyperaemia 28.22 14.44 8 23523 180 50581413
Hyperaesthesia 27.81 14.44 26 23505 8147 50573446
Myoglobin blood increased 27.56 14.44 13 23518 1280 50580313
Muscle rigidity 27.34 14.44 28 23503 9801 50571792
Pituitary apoplexy 26.77 14.44 7 23524 115 50581478
Acute respiratory failure 26.71 14.44 48 23483 28734 50552859
Arrhythmia 26.69 14.44 52 23479 33080 50548513
Rash 26.60 14.44 109 23422 437362 50144231
Carcinoid crisis 26.59 14.44 8 23523 223 50581370
Depressed level of consciousness 26.57 14.44 68 23463 51885 50529708
Exposure during pregnancy 26.48 14.44 119 23412 120896 50460697
Product administered to patient of inappropriate age 26.37 14.44 16 23515 2614 50578979
Procedural hypotension 26.36 14.44 12 23519 1090 50580503
Clonus 26.29 14.44 19 23512 4156 50577437
Dyschezia 26.25 14.44 14 23517 1790 50579803
Left ventricular hypertrophy 25.93 14.44 20 23511 4825 50576768
Oliguria 25.79 14.44 25 23506 8191 50573402
Back pain 25.78 14.44 39 23492 219991 50361602
Contusion 25.68 14.44 10 23521 112173 50469420
Frequent bowel movements 25.63 14.44 32 23499 13886 50567707
Ventricular tachycardia 25.42 14.44 34 23497 15787 50565806
Delayed graft function 25.03 14.44 11 23520 919 50580674
Infection parasitic 24.28 14.44 8 23523 302 50581291
Myalgia 24.00 14.44 14 23517 124305 50457288
Asthma 23.96 14.44 6 23525 89331 50492262
Premature delivery 23.95 14.44 41 23490 23622 50557971
Asthenia 23.71 14.44 73 23458 318969 50262624
Acidosis hyperchloraemic 23.60 14.44 8 23523 330 50581263
Drug reaction with eosinophilia and systemic symptoms 23.37 14.44 45 23486 28379 50553214
Patent ductus arteriosus 23.18 14.44 17 23514 3803 50577790
Nail dystrophy 23.16 14.44 10 23521 801 50580792
Cardio-respiratory arrest 23.01 14.44 66 23465 53826 50527767
Tachypnoea 22.92 14.44 31 23500 14546 50567047
Atrioventricular dissociation 22.50 14.44 7 23524 219 50581374
Mixed liver injury 22.40 14.44 16 23515 3435 50578158
Intensive care unit delirium 22.40 14.44 5 23526 40 50581553
Electrocardiogram repolarisation abnormality 22.36 14.44 11 23520 1189 50580404
Palpitations 22.34 14.44 8 23523 94498 50487095
Tonic clonic movements 22.04 14.44 11 23520 1226 50580367
Abdominal pain upper 21.97 14.44 25 23506 159284 50422309
Methaemoglobinaemia 21.97 14.44 13 23518 2029 50579564
Myocardial ischaemia 21.87 14.44 27 23504 11586 50570007
White matter lesion 21.82 14.44 12 23519 1630 50579963
Overdose 21.76 14.44 98 23433 99629 50481964
Procedural complication 21.74 14.44 18 23513 4805 50576788
Hypersensitivity 21.67 14.44 42 23489 215119 50366474
Intentional overdose 21.52 14.44 71 23460 62433 50519160
Apnoeic attack 21.40 14.44 7 23524 258 50581335
Nephrocalcinosis 21.40 14.44 10 23521 964 50580629
Blood lactate dehydrogenase increased 21.27 14.44 35 23496 19527 50562066
Intensive care unit acquired weakness 21.24 14.44 9 23522 688 50580905
Bronchitis 21.16 14.44 11 23520 104148 50477445
Neurotoxicity 21.16 14.44 30 23501 14710 50566883
Paralysis 21.10 14.44 23 23508 8641 50572952
Laryngospasm 21.08 14.44 14 23517 2674 50578919
Anuria 20.94 14.44 26 23505 11218 50570375
Post procedural stroke 20.89 14.44 5 23526 56 50581537
Granulomatous liver disease 20.69 14.44 9 23522 734 50580859
Hypoventilation 20.58 14.44 16 23515 3905 50577688
Haematemesis 20.52 14.44 42 23489 27683 50553910
Therapeutic product effect prolonged 20.26 14.44 7 23524 306 50581287
Impaired healing 20.09 14.44 4 23527 69782 50511811
C-reactive protein decreased 20.02 14.44 9 23522 794 50580799
Pulmonary oedema 19.99 14.44 59 23472 48879 50532714
Euthyroid sick syndrome 19.93 14.44 5 23526 69 50581524
Hypoaesthesia 19.79 14.44 18 23513 127239 50454354
Psoriasis 19.77 14.44 4 23527 68996 50512597
Coronary artery embolism 19.69 14.44 6 23525 175 50581418
Blood magnesium decreased 19.51 14.44 25 23506 11135 50570458
Hypovolaemia 19.44 14.44 23 23508 9442 50572151
Posterior reversible encephalopathy syndrome 19.42 14.44 29 23502 14899 50566694
Large intestinal ulcer 19.40 14.44 14 23517 3055 50578538
Tonsillar hypertrophy 19.37 14.44 9 23522 857 50580736
Immunosuppressant drug level increased 19.35 14.44 14 23517 3068 50578525
Pneumonia fungal 19.21 14.44 16 23515 4304 50577289
Hypochloraemia 19.08 14.44 11 23520 1636 50579957
Intermittent claudication 19.03 14.44 11 23520 1644 50579949
Ventricular dysfunction 18.99 14.44 13 23518 2608 50578985
Local anaesthetic systemic toxicity 18.98 14.44 8 23523 604 50580989
Neonatal seizure 18.90 14.44 7 23524 375 50581218
Septic shock 18.84 14.44 64 23467 57111 50524482
Airway complication of anaesthesia 18.78 14.44 6 23525 205 50581388
Sinus arrest 18.77 14.44 11 23520 1687 50579906
Stevens-Johnson syndrome 18.58 14.44 35 23496 21717 50559876
Hepatic enzyme increased 18.47 14.44 22 23509 137358 50444235
Hypertrophic cardiomyopathy 18.35 14.44 10 23521 1335 50580258
Acute hepatic failure 18.34 14.44 29 23502 15648 50565945
Symptom masked 18.29 14.44 8 23523 661 50580932
Renal infarct 18.24 14.44 10 23521 1350 50580243
Colitis ulcerative 18.12 14.44 30 23501 16824 50564769
Coronary artery bypass 18.12 14.44 12 23519 2281 50579312
Burkholderia test positive 18.02 14.44 6 23525 234 50581359
Selective eating disorder 17.99 14.44 11 23520 1821 50579772
Hyperammonaemia 17.97 14.44 16 23515 4708 50576885
Resuscitation 17.96 14.44 9 23522 1012 50580581
Pseudomonas infection 17.88 14.44 22 23509 9408 50572185
Device related sepsis 17.85 14.44 14 23517 3461 50578132
Gastrointestinal vascular malformation 17.71 14.44 4 23527 34 50581559
Respiratory rate increased 17.58 14.44 24 23507 11361 50570232
Extremity necrosis 17.51 14.44 10 23521 1461 50580132
Foetal exposure during pregnancy 17.43 14.44 39 23492 27320 50554273
Stomatitis 17.41 14.44 13 23518 101331 50480262
Blood potassium increased 17.38 14.44 29 23502 16369 50565224
Musculoskeletal pain 17.25 14.44 6 23525 72171 50509422
Epileptic encephalopathy 17.20 14.44 6 23525 270 50581323
Post procedural haemorrhage 17.19 14.44 19 23512 7251 50574342
Influenza like illness 17.17 14.44 3 23528 57456 50524137
Hypotonia 17.10 14.44 20 23511 8114 50573479
Electrocardiogram QT prolonged 17.02 14.44 58 23473 51828 50529765
Injection site pain 16.91 14.44 16 23515 111008 50470585
Neuromuscular blockade 16.91 14.44 6 23525 284 50581309
Teratoma 16.88 14.44 5 23526 132 50581461
Axillary pain 16.82 14.44 10 23521 1574 50580019
Coagulopathy 16.74 14.44 30 23501 17914 50563679
Oral candidiasis 16.72 14.44 29 23502 16886 50564707
Hypokalaemia 16.66 14.44 83 23448 87909 50493684
Tracheal injury 16.62 14.44 4 23527 46 50581547
Drug chemical incompatibility 16.54 14.44 4 23527 47 50581546
Loss of personal independence in daily activities 16.44 14.44 6 23525 70044 50511549
Vulvovaginal candidiasis 16.38 14.44 12 23519 2680 50578913
Anaphylactoid shock 16.37 14.44 6 23525 312 50581281
Hyperthermia 16.30 14.44 19 23512 7677 50573916
Infantile apnoea 16.26 14.44 8 23523 865 50580728
Wrong product administered 16.25 14.44 16 23515 5344 50576249
Blood cholesterol increased 16.25 14.44 3 23528 55212 50526381
Gait disturbance 16.23 14.44 28 23503 149977 50431616
Procedural intestinal perforation 16.18 14.44 5 23526 153 50581440
Ill-defined disorder 16.01 14.44 3 23528 54651 50526942
Catheter site haemorrhage 15.92 14.44 12 23519 2798 50578795
Sepsis 15.85 14.44 111 23420 132814 50448779
Rash morbilliform 15.78 14.44 12 23519 2834 50578759
Enzyme induction 15.76 14.44 4 23527 58 50581535
Manipulation 15.76 14.44 4 23527 58 50581535
Gaze palsy 15.70 14.44 9 23522 1324 50580269
Coma hepatic 15.66 14.44 7 23524 609 50580984
Oxygen saturation immeasurable 15.63 14.44 3 23528 10 50581583
Radiculopathy 15.44 14.44 15 23516 4926 50576667
Urinary tract infection 15.41 14.44 53 23478 223967 50357626
White blood cell count decreased 15.36 14.44 19 23512 116703 50464890
Dyspnoea 15.30 14.44 172 23359 547436 50034157
Cor pulmonale 15.21 14.44 10 23521 1877 50579716
Respiratory arrest 15.05 14.44 39 23492 29970 50551623
Premature baby 15.04 14.44 29 23502 18308 50563285
Coma 14.81 14.44 59 23472 56820 50524773
Influenza 14.73 14.44 12 23519 89526 50492067
Pruritus 14.61 14.44 75 23456 283493 50298100
Therapeutic product effect variable 14.58 14.44 8 23523 1082 50580511
Fear 14.45 14.44 25 23506 14524 50567069

FDA Adverse Event Reporting System (Male)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Status epilepticus 216.04 14.24 123 22846 10671 29540887
Drug ineffective 160.20 14.24 629 22340 362541 29189017
Hypotension 153.12 14.24 411 22558 193943 29357615
Drug reaction with eosinophilia and systemic symptoms 148.43 14.24 143 22826 27849 29523709
Hyperthermia malignant 141.59 14.24 53 22916 1731 29549827
Anaphylactic reaction 140.83 14.24 138 22831 27435 29524123
Cardiac arrest 139.15 14.24 243 22726 85348 29466210
Bradycardia 133.20 14.24 206 22763 65423 29486135
Serotonin syndrome 119.31 14.24 103 22866 17409 29534149
Multiple-drug resistance 110.45 14.24 56 22913 3844 29547714
Propofol infusion syndrome 102.43 14.24 34 22935 773 29550785
Intensive care unit acquired weakness 97.24 14.24 34 22935 909 29550649
Myoclonus 92.11 14.24 79 22890 13230 29538328
Fatigue 91.30 14.24 68 22901 316753 29234805
Delirium 87.43 14.24 129 22840 39268 29512290
Metabolic acidosis 86.00 14.24 125 22844 37537 29514021
Drug ineffective for unapproved indication 83.70 14.24 77 22892 14137 29537421
Anaphylactic shock 81.96 14.24 74 22895 13262 29538296
Respiratory failure 79.81 14.24 209 22760 96922 29454636
Diarrhoea 71.99 14.24 92 22877 332606 29218952
Coma 71.92 14.24 118 22851 39332 29512226
Off label use 71.20 14.24 437 22532 300363 29251195
Dizziness 69.88 14.24 30 22939 189654 29361904
Respiratory depression 67.73 14.24 67 22902 13456 29538102
Autonomic nervous system imbalance 66.93 14.24 34 22935 2342 29549216
Diabetes insipidus 66.16 14.24 34 22935 2400 29549158
Tachycardia 65.88 14.24 162 22807 72248 29479310
Acute respiratory distress syndrome 61.10 14.24 82 22887 22853 29528705
Hypoxia 58.80 14.24 120 22849 47259 29504299
Brain oedema 58.35 14.24 59 22910 12161 29539397
Multiple organ dysfunction syndrome 58.24 14.24 142 22827 62974 29488584
Rhabdomyolysis 57.38 14.24 138 22831 60670 29490888
Acidosis hyperchloraemic 56.72 14.24 18 22951 353 29551205
Generalised tonic-clonic seizure 56.53 14.24 72 22897 19067 29532491
Product dose omission issue 56.43 14.24 5 22964 96378 29455180
Sedation 53.83 14.24 67 22902 17338 29534220
Depressed level of consciousness 53.66 14.24 100 22869 36842 29514716
COVID-19 pneumonia 52.99 14.24 50 22919 9472 29542086
Septic shock 52.74 14.24 136 22833 62424 29489134
Drug interaction 52.51 14.24 296 22673 197089 29354469
Unresponsive to stimuli 52.47 14.24 80 22889 25046 29526512
Delayed recovery from anaesthesia 52.03 14.24 20 22949 703 29550855
Headache 51.74 14.24 36 22933 173971 29377587
Seizure like phenomena 51.14 14.24 19 22950 607 29550951
Anaesthetic complication neurological 50.65 14.24 16 22953 309 29551249
Agitation 50.09 14.24 118 22851 51186 29500372
Nausea 50.01 14.24 93 22876 289162 29262396
Necrosis ischaemic 46.77 14.24 14 22955 224 29551334
Hyperthermia 45.88 14.24 46 22923 9384 29542174
Respiratory acidosis 45.76 14.24 33 22936 4295 29547263
Catatonia 44.82 14.24 33 22936 4435 29547123
Anaesthetic complication 42.79 14.24 19 22950 967 29550591
Haemodynamic instability 42.29 14.24 41 22928 8032 29543526
Hypertransaminasaemia 41.60 14.24 29 22940 3577 29547981
Shock 40.31 14.24 65 22904 21339 29530219
Arthralgia 40.02 14.24 30 22939 139587 29411971
Hyperammonaemia 39.95 14.24 34 22935 5629 29545929
Sedation complication 38.03 14.24 19 22950 1263 29550295
Long QT syndrome 37.96 14.24 23 22946 2235 29549323
Laryngospasm 37.92 14.24 19 22950 1271 29550287
Toxicity to various agents 37.60 14.24 247 22722 173414 29378144
Fall 37.16 14.24 50 22919 177128 29374430
Product administered to patient of inappropriate age 36.98 14.24 24 22945 2631 29548927
Pain in extremity 36.74 14.24 20 22949 110413 29441145
Stress cardiomyopathy 36.54 14.24 20 22949 1604 29549954
Seizure 36.40 14.24 156 22813 92967 29458591
Burkholderia test positive 36.26 14.24 17 22952 982 29550576
Pulseless electrical activity 36.21 14.24 34 22935 6400 29545158
Myalgia 35.80 14.24 7 22962 74012 29477546
Herpes simplex viraemia 35.73 14.24 9 22960 72 29551486
Asthenia 35.58 14.24 71 22898 215179 29336379
Peripheral swelling 35.49 14.24 4 22965 63735 29487823
Mucosal ulceration 35.00 14.24 16 22953 872 29550686
Electroencephalogram abnormal 34.73 14.24 22 22947 2313 29549245
Coagulopathy 34.56 14.24 55 22914 17852 29533706
Kounis syndrome 34.32 14.24 20 22949 1809 29549749
Artery dissection 33.68 14.24 9 22960 93 29551465
Pruritus 33.61 14.24 25 22944 116824 29434734
Corneal reflex decreased 33.47 14.24 10 22959 159 29551399
Toxic epidermal necrolysis 32.65 14.24 54 22915 18099 29533459
Apnoea 31.98 14.24 31 22938 6071 29545487
Rash maculo-papular 31.88 14.24 63 22906 24226 29527332
Dyspnoea 31.38 14.24 139 22830 326593 29224965
Intestinal ischaemia 31.38 14.24 32 22937 6660 29544898
Dyskinesia 31.26 14.24 56 22913 20005 29531553
Back pain 30.57 14.24 21 22948 102263 29449295
Cardiogenic shock 30.46 14.24 54 22915 19136 29532422
Hypercapnia 29.68 14.24 24 22945 3702 29547856
Blood lactic acid increased 29.67 14.24 29 22940 5737 29545821
Death 29.65 14.24 151 22818 341933 29209625
Respiratory arrest 29.19 14.24 63 22906 25770 29525788
Circulatory collapse 28.93 14.24 52 22917 18621 29532937
Trigemino-cardiac reflex 28.67 14.24 9 22960 170 29551388
Haemophagocytic lymphohistiocytosis 28.64 14.24 38 22931 10466 29541092
Behaviour disorder 28.18 14.24 23 22946 3593 29547965
Post procedural hypotension 27.68 14.24 7 22962 57 29551501
Superinfection 27.65 14.24 18 22951 1983 29549575
Dehydration 27.64 14.24 29 22940 114719 29436839
Myocardial infarction 27.56 14.24 27 22942 110269 29441289
Neuromuscular block prolonged 26.99 14.24 11 22958 452 29551106
Anticonvulsant drug level below therapeutic 26.93 14.24 12 22957 616 29550942
Intracranial pressure increased 26.81 14.24 22 22947 3463 29548095
Oxygen saturation decreased 26.52 14.24 86 22883 44851 29506707
Malignant catatonia 26.42 14.24 9 22960 222 29551336
Intensive care 26.03 14.24 10 22959 351 29551207
Muscle rigidity 25.59 14.24 34 22935 9377 29542181
Ventricular tachycardia 25.44 14.24 55 22914 22519 29529039
Neuroleptic malignant syndrome 25.06 14.24 45 22924 16103 29535455
Odynophagia 24.99 14.24 24 22945 4646 29546912
Drug resistance 24.88 14.24 53 22916 21487 29530071
Acidosis 24.77 14.24 34 22935 9671 29541887
Overdose 24.74 14.24 125 22844 79694 29471864
Liver function test 24.53 14.24 6 22963 42 29551516
Nasopharyngitis 24.32 14.24 8 22961 59657 29491901
Abdominal discomfort 24.31 14.24 4 22965 47899 29503659
Hepatitis fulminant 24.29 14.24 21 22948 3550 29548008
Hypoventilation 24.12 14.24 19 22950 2822 29548736
Upper airway obstruction 23.97 14.24 11 22958 605 29550953
Laryngomalacia 23.75 14.24 9 22960 304 29551254
Leukocytosis 23.25 14.24 51 22918 21091 29530467
Hyperammonaemic encephalopathy 22.95 14.24 16 22953 1974 29549584
Drug withdrawal syndrome 22.82 14.24 46 22923 17938 29533620
Large intestine anastomosis 22.81 14.24 6 22963 58 29551500
Periorbital swelling 22.53 14.24 9 22960 351 29551207
White blood cell count decreased 22.50 14.24 19 22950 83343 29468215
Cyanosis 22.28 14.24 35 22934 11232 29540326
Tachypnoea 22.03 14.24 41 22928 15074 29536484
Neuropathy peripheral 22.00 14.24 14 22955 71013 29480545
Blood pressure decreased 21.60 14.24 81 22888 45396 29506162
Decreased appetite 21.44 14.24 51 22918 145291 29406267
Neurological examination abnormal 21.37 14.24 8 22961 261 29551297
Mixed dementia 21.14 14.24 8 22961 269 29551289
Mumps 20.99 14.24 6 22963 81 29551477
Diabetes mellitus 20.95 14.24 3 22966 39828 29511730
Urinary bladder rupture 20.79 14.24 6 22963 84 29551474
Partial seizures 20.77 14.24 20 22949 3883 29547675
Hypoglycaemia 20.57 14.24 6 22963 48340 29503218
Brain death 20.44 14.24 16 22953 2354 29549204
Dyspnoea paroxysmal nocturnal 20.40 14.24 13 22956 1381 29550177
Areflexia 20.38 14.24 17 22952 2737 29548821
Procedural complication 20.11 14.24 20 22949 4040 29547518
Medical device site fistula 19.96 14.24 5 22964 39 29551519
Illusion 19.64 14.24 10 22959 692 29550866
Product use in unapproved indication 19.62 14.24 125 22844 86750 29464808
Neutropenia 19.60 14.24 46 22923 131665 29419893
Hepatic cytolysis 19.46 14.24 28 22941 8319 29543239
Drug withdrawal syndrome neonatal 19.22 14.24 18 22951 3377 29548181
Hypernatraemia 19.04 14.24 26 22943 7360 29544198
Hospitalisation 19.03 14.24 6 22963 45982 29505576
Hyperaesthesia 18.89 14.24 18 22951 3451 29548107
Encephalopathy 18.84 14.24 60 22909 30983 29520575
Cardiac failure congestive 18.83 14.24 19 22950 76562 29474996
Respiratory disorder 18.71 14.24 41 22928 16942 29534616
Respiratory rate decreased 18.69 14.24 14 22955 1931 29549627
COVID-19 18.66 14.24 66 22903 35948 29515610
Heart alternation 18.48 14.24 3 22966 0 29551558
Weight decreased 18.48 14.24 58 22911 150847 29400711
Postresuscitation encephalopathy 18.43 14.24 4 22965 15 29551543
Electrocardiogram ST segment elevation 18.42 14.24 20 22949 4472 29547086
Stupor 18.39 14.24 16 22953 2728 29548830
Disease progression 18.30 14.24 22 22947 81894 29469664
Angle closure glaucoma 18.12 14.24 10 22959 815 29550743
Neurotoxicity 18.09 14.24 37 22932 14576 29536982
Atonic urinary bladder 17.84 14.24 4 22965 18 29551540
Parkinsonism 17.83 14.24 25 22944 7253 29544305
Constipation 17.69 14.24 39 22930 114121 29437437
Vomiting 17.60 14.24 95 22874 212165 29339393
Arthrofibrosis 17.32 14.24 5 22964 70 29551488
Ventricular fibrillation 17.19 14.24 38 22931 15795 29535763
Anaemia 17.18 14.24 89 22880 200862 29350696
Malaise 17.07 14.24 65 22904 159537 29392021
Periventricular haemorrhage neonatal 16.88 14.24 4 22965 24 29551534
Psychotic disorder 16.87 14.24 44 22925 20310 29531248
Electrocardiogram QT prolonged 16.85 14.24 64 22905 36073 29515485
Respiratory distress 16.78 14.24 59 22910 32047 29519511
Administration related reaction 16.59 14.24 5 22964 82 29551476
Haematuria traumatic 16.41 14.24 6 22963 183 29551375
Encephalitis autoimmune 16.24 14.24 8 22961 516 29551042
Klebsiella infection 16.19 14.24 24 22945 7325 29544233
Muscle spasms 16.17 14.24 16 22953 65066 29486492
Neuromuscular blockade 16.05 14.24 6 22963 195 29551363
Haemoglobin decreased 16.00 14.24 38 22931 108337 29443221
Product packaging confusion 15.88 14.24 4 22965 32 29551526
Aggression 15.80 14.24 62 22907 35479 29516079
Pain 15.76 14.24 74 22895 171358 29380200
Weight increased 15.67 14.24 22 22947 76645 29474913
Hyperexplexia 15.67 14.24 4 22965 34 29551524
Catecholamine crisis 15.56 14.24 4 22965 35 29551523
Pneumomediastinum 15.46 14.24 12 22957 1744 29549814
Epilepsy 15.43 14.24 40 22929 18392 29533166
Systemic inflammatory response syndrome 15.33 14.24 21 22948 5960 29545598
Abdominal compartment syndrome 15.28 14.24 9 22960 830 29550728
Abdominal pain upper 15.14 14.24 15 22954 60978 29490580
Sinusitis 15.10 14.24 4 22965 34346 29517212
Product contamination 14.98 14.24 8 22961 611 29550947
Bronchitis 14.92 14.24 5 22964 36863 29514695
Endotracheal intubation 14.82 14.24 14 22955 2655 29548903
Cardio-respiratory arrest 14.80 14.24 78 22891 50523 29501035
Asthma 14.77 14.24 4 22965 33845 29517713
Hypoaesthesia 14.65 14.24 12 22957 53455 29498103
Postoperative delirium 14.50 14.24 4 22965 47 29551511
Hypertriglyceridaemia 14.48 14.24 23 22946 7452 29544106
Chest pain 14.44 14.24 42 22927 111931 29439627
Nervous system disorder 14.42 14.24 31 22938 12643 29538915
Buttock injury 14.27 14.24 4 22965 50 29551508
Somnolence 14.25 14.24 123 22846 93832 29457726

FDA Adverse Event Reporting System (Geriatric)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Status epilepticus 441.55 13.74 237 42680 21426 64434389
Hypotension 337.65 13.74 766 42151 380208 64075607
Cardiac arrest 327.06 13.74 455 42462 153609 64302206
Anaphylactic reaction 299.76 13.74 294 42623 68370 64387445
Serotonin syndrome 283.81 13.74 224 42693 39058 64416757
Multiple-drug resistance 266.69 13.74 115 42802 6387 64449428
Drug ineffective 263.55 13.74 1178 41739 839069 63616746
Propofol infusion syndrome 244.46 13.74 75 42842 1542 64454273
Fatigue 183.28 13.74 139 42778 748591 63707224
Diabetes insipidus 175.74 13.74 77 42840 4444 64451371
Metabolic acidosis 175.47 13.74 226 42691 70732 64385083
Bradycardia 172.82 13.74 294 42623 117925 64337890
Tachycardia 166.91 13.74 331 42586 149248 64306567
Myoclonus 161.81 13.74 134 42783 24984 64430831
Anaphylactic shock 159.34 13.74 144 42773 30184 64425631
Drug reaction with eosinophilia and systemic symptoms 157.05 13.74 187 42730 54030 64401785
Drug interaction 155.30 13.74 561 42356 361522 64094293
Drug ineffective for unapproved indication 152.23 13.74 142 42775 30991 64424824
Hyperthermia malignant 150.62 13.74 58 42859 2401 64453414
Respiratory acidosis 144.56 13.74 87 42830 9768 64446047
Multiple organ dysfunction syndrome 137.47 13.74 244 42673 101169 64354646
Respiratory failure 134.31 13.74 317 42600 160866 64294949
Delirium 127.03 13.74 191 42726 69003 64386812
Generalised tonic-clonic seizure 126.31 13.74 144 42773 39713 64416102
Joint swelling 125.23 13.74 4 42913 215378 64240437
Agitation 124.14 13.74 216 42701 88151 64367664
Arthralgia 121.49 13.74 72 42845 442188 64013627
Diarrhoea 121.15 13.74 184 42733 722520 63733295
Off label use 120.97 13.74 776 42141 632030 63823785
Nausea 117.91 13.74 215 42702 785585 63670230
Intensive care unit acquired weakness 113.92 13.74 43 42874 1684 64454131
Anaesthetic complication 113.64 13.74 48 42869 2531 64453284
Unresponsive to stimuli 111.43 13.74 152 42765 50241 64405574
Seizure 108.61 13.74 299 42618 166593 64289222
Circulatory collapse 107.10 13.74 122 42795 33610 64422205
Fall 106.07 13.74 74 42843 416752 64039063
Pain 104.64 13.74 129 42788 553382 63902433
Headache 101.55 13.74 122 42795 529345 63926470
Hypoxia 100.55 13.74 197 42720 87952 64367863
Respiratory depression 99.63 13.74 99 42818 23344 64432471
Necrosis ischaemic 97.06 13.74 33 42884 950 64454865
Delayed recovery from anaesthesia 97.02 13.74 37 42880 1491 64454324
Intestinal ischaemia 96.83 13.74 72 42845 11477 64444338
Peripheral swelling 95.54 13.74 13 42904 209140 64246675
Shock 94.79 13.74 122 42795 38118 64417697
Acute respiratory distress syndrome 94.61 13.74 123 42794 38812 64417003
Dizziness 92.55 13.74 90 42827 430073 64025742
Pain in extremity 92.51 13.74 43 42874 303042 64152773
Encephalopathy 86.81 13.74 147 42770 58672 64397143
Pulseless electrical activity 86.31 13.74 70 42847 12669 64443146
Apnoea 85.20 13.74 64 42853 10358 64445457
Labile blood pressure 82.71 13.74 36 42881 2044 64453771
Brain oedema 82.51 13.74 87 42830 21988 64433827
Abdominal discomfort 81.69 13.74 12 42905 182310 64273505
Anaesthetic complication neurological 81.20 13.74 25 42892 520 64455295
Haemodynamic instability 80.66 13.74 72 42845 14840 64440975
Alopecia 78.82 13.74 9 42908 165681 64290134
Product dose omission issue 78.20 13.74 17 42900 194730 64261085
Electroencephalogram abnormal 76.48 13.74 46 42871 5157 64450658
Acidosis hyperchloraemic 75.33 13.74 25 42892 667 64455148
Depressed level of consciousness 75.30 13.74 167 42750 81269 64374546
Drug intolerance 74.30 13.74 17 42900 187975 64267840
Partial seizures 73.76 13.74 51 42866 7256 64448559
Nasopharyngitis 73.10 13.74 20 42897 196053 64259762
Coma 72.54 13.74 172 42745 87443 64368372
Intra-abdominal pressure increased 71.42 13.74 19 42898 228 64455587
Myoglobin urine present 71.02 13.74 23 42894 567 64455248
Mitochondrial DNA mutation 70.53 13.74 19 42898 240 64455575
Rhabdomyolysis 69.47 13.74 174 42743 91552 64364263
Systemic inflammatory response syndrome 68.83 13.74 56 42861 10179 64445636
Cardiogenic shock 65.98 13.74 94 42823 32333 64423482
Unwanted awareness during anaesthesia 64.15 13.74 18 42899 267 64455548
Blood lactic acid increased 63.89 13.74 54 42863 10347 64445468
Neuromuscular block prolonged 63.27 13.74 24 42893 953 64454862
Septic shock 62.76 13.74 183 42734 105254 64350561
Stress cardiomyopathy 60.88 13.74 50 42867 9207 64446608
Asthenia 60.55 13.74 121 42796 427923 64027892
Malaise 60.45 13.74 107 42810 396140 64059675
Swelling 58.49 13.74 17 42900 160201 64295614
Electrocardiogram ST segment elevation 58.06 13.74 44 42873 7215 64448600
Toxicity to various agents 57.97 13.74 427 42490 363086 64092729
Hyperthermia 57.60 13.74 61 42856 15489 64440326
Myalgia 57.59 13.74 17 42900 158600 64297215
Upper airway obstruction 57.39 13.74 24 42893 1234 64454581
Laryngospasm 57.31 13.74 33 42884 3412 64452403
Oxygen saturation decreased 57.18 13.74 179 42738 106997 64348818
Oxygen saturation abnormal 56.21 13.74 33 42884 3538 64452277
Weight increased 55.34 13.74 37 42880 213311 64242504
Autonomic nervous system imbalance 54.27 13.74 34 42883 4098 64451717
Renal ischaemia 53.94 13.74 22 42895 1061 64454754
Hyperammonaemia 53.92 13.74 48 42869 9856 64445959
Infusion related reaction 53.86 13.74 21 42896 164446 64291369
Muscle rigidity 53.44 13.74 62 42855 17411 64438404
Back pain 52.96 13.74 53 42864 250118 64205697
Electrocardiogram QRS complex prolonged 52.72 13.74 46 42871 9198 64446617
Pneumatosis 52.68 13.74 20 42897 796 64455019
Ventricular tachycardia 51.02 13.74 86 42831 34179 64421636
Product administered to patient of inappropriate age 50.93 13.74 34 42883 4567 64451248
PCO2 increased 50.90 13.74 24 42893 1643 64454172
Coagulopathy 50.05 13.74 82 42835 31838 64423977
Hyperammonaemic encephalopathy 49.83 13.74 32 42885 4026 64451789
Anaesthetic complication pulmonary 49.16 13.74 11 42906 59 64455756
Pruritus 48.85 13.74 83 42834 312317 64143498
Seizure like phenomena 48.05 13.74 23 42894 1629 64454186
Foetal death 47.55 13.74 36 42881 5894 64449921
Sinusitis 47.18 13.74 19 42898 145909 64309906
Hypoventilation 47.14 13.74 36 42881 5970 64449845
Mydriasis 46.27 13.74 54 42863 15258 64440557
Catatonia 45.65 13.74 39 42878 7581 64448234
Hepatic ischaemia 44.96 13.74 19 42898 1003 64454812
COVID-19 pneumonia 44.62 13.74 55 42862 16449 64439366
Toxic encephalopathy 44.59 13.74 43 42874 9772 64446043
PO2 increased 44.09 13.74 21 42896 1471 64454344
Dyspnoea 44.08 13.74 289 42628 718385 63737430
Muscle relaxant therapy 43.67 13.74 12 42905 164 64455651
Oropharyngeal oedema 43.58 13.74 13 42904 242 64455573
Epileptic aura 42.92 13.74 10 42907 66 64455749
Perforation 42.83 13.74 19 42898 1129 64454686
Weight decreased 42.78 13.74 78 42839 285661 64170154
Encephalitis autoimmune 42.29 13.74 22 42895 1862 64453953
Ventricular extrasystoles 41.98 13.74 55 42862 17474 64438341
Hypernatraemia 41.96 13.74 46 42871 12143 64443672
Hypertransaminasaemia 41.45 13.74 36 42881 7155 64448660
Tachypnoea 41.31 13.74 68 42849 26503 64429312
Toxic epidermal necrolysis 41.06 13.74 82 42835 37084 64418731
Abdominal pain upper 40.68 13.74 34 42883 174996 64280819
Leukocytosis 40.19 13.74 82 42835 37658 64418157
Systemic lupus erythematosus 40.13 13.74 3 42914 77609 64378206
Anorectal ulcer 39.95 13.74 9 42908 50 64455765
Non-consummation 39.95 13.74 9 42908 50 64455765
Neurotoxicity 39.77 13.74 68 42849 27336 64428479
Rash maculo-papular 39.64 13.74 93 42824 46933 64408882
Troponin increased 39.52 13.74 50 42867 15349 64440466
Epilepsy 39.49 13.74 76 42841 33455 64422360
Procedural complication 39.13 13.74 35 42882 7230 64448585
Ventricular hypokinesia 39.05 13.74 36 42881 7733 64448082
Product use in unapproved indication 38.79 13.74 225 42692 176393 64279422
Arthritis 38.74 13.74 5 42912 83809 64372006
Long QT syndrome 38.58 13.74 30 42887 5109 64450706
Bronchospasm 38.55 13.74 59 42858 21623 64434192
Clonus 38.29 13.74 32 42885 6035 64449780
Pseudopolyp 37.73 13.74 13 42904 390 64455425
Anticholinergic syndrome 37.69 13.74 23 42894 2646 64453169
Overdose 37.49 13.74 207 42710 159359 64296456
Respiratory arrest 37.49 13.74 98 42819 52887 64402928
Artery dissection 37.17 13.74 11 42906 199 64455616
Bronchitis 37.08 13.74 13 42904 108730 64347085
Altered state of consciousness 36.46 13.74 79 42838 37823 64417992
Diabetic macroangiopathy 36.37 13.74 10 42907 137 64455678
Hypoaesthesia 36.22 13.74 24 42893 139084 64316731
Carcinoid crisis 36.21 13.74 13 42904 441 64455374
Sinus bradycardia 36.15 13.74 59 42858 22834 64432981
Electrocardiogram ST segment depression 35.98 13.74 27 42890 4362 64451453
Herpes zoster 35.94 13.74 5 42912 79182 64376633
Ultrasound ovary abnormal 35.60 13.74 9 42908 87 64455728
Trigemino-cardiac reflex 35.54 13.74 11 42906 233 64455582
Anticonvulsant drug level below therapeutic 35.18 13.74 16 42901 1008 64454807
Blood creatine phosphokinase increased 35.17 13.74 102 42815 58456 64397359
Asthma 34.93 13.74 10 42907 95215 64360600
Dehydration 34.40 13.74 57 42860 216706 64239109
Disseminated intravascular coagulation 34.10 13.74 70 42847 32278 64423537
Blood pH decreased 33.70 13.74 26 42891 4376 64451439
Urinary tract infection 33.09 13.74 65 42852 231531 64224284
Tonic clonic movements 32.95 13.74 19 42898 1970 64453845
Hepatic failure 32.80 13.74 96 42821 55298 64400517
Kounis syndrome 32.63 13.74 22 42895 3003 64452812
Discomfort 32.56 13.74 7 42910 80871 64374944
Dyskinesia 32.22 13.74 77 42840 39311 64416504
Aggression 32.19 13.74 85 42832 46147 64409668
Decreased appetite 32.12 13.74 89 42828 281200 64174615
Wound 32.08 13.74 6 42911 76471 64379344
Paradoxical drug reaction 32.01 13.74 29 42888 6091 64449724
Corneal reflex decreased 31.67 13.74 11 42906 338 64455477
Intestinal infarction 31.65 13.74 16 42901 1275 64454540
Psoriasis 31.45 13.74 5 42912 71698 64384117
Procedural hypotension 31.20 13.74 18 42899 1868 64453947
Neuroleptic malignant syndrome 31.10 13.74 58 42859 24938 64430877
Neuromuscular blockade 31.04 13.74 12 42905 502 64455313
Acute respiratory failure 30.97 13.74 88 42829 49846 64405969
Musculoskeletal pain 30.83 13.74 8 42909 81286 64374529
Unmasking of previously unidentified disease 30.71 13.74 17 42900 1630 64454185
Injection site pain 30.69 13.74 18 42899 111390 64344425
Cardiotoxicity 30.65 13.74 36 42881 10238 64445577
White blood cell count decreased 30.54 13.74 36 42881 157801 64298014
Ventricular fibrillation 30.48 13.74 56 42861 23804 64432011
Cardio-respiratory arrest 30.43 13.74 138 42779 98255 64357560
Palpitations 30.05 13.74 16 42901 104472 64351343
Hypercapnia 29.96 13.74 31 42886 7663 64448152
Airway complication of anaesthesia 29.89 13.74 11 42906 401 64455414
Hyperaesthesia 29.73 13.74 35 42882 9979 64445836
Acidosis 29.65 13.74 47 42870 17748 64438067
Blood gases abnormal 29.55 13.74 14 42903 969 64454846
Blood bicarbonate decreased 29.51 13.74 25 42892 4804 64451011
Behaviour disorder 29.13 13.74 24 42893 4438 64451377
Arthrofibrosis 29.07 13.74 8 42909 110 64455705
Laryngeal stenosis 28.97 13.74 13 42904 794 64455021
Fluid retention 28.93 13.74 3 42914 59603 64396212
Acid base balance abnormal 28.80 13.74 10 42907 307 64455508
Respiratory distress 28.44 13.74 88 42829 52243 64403572
Airway peak pressure increased 28.20 13.74 10 42907 327 64455488
Hypotonia 28.13 13.74 36 42881 11176 64444639
Electrocardiogram QT prolonged 28.07 13.74 116 42801 79332 64376483
Post procedural hypotension 27.94 13.74 7 42910 65 64455750
Lower respiratory tract infection 27.94 13.74 14 42903 94600 64361215
Procedural vomiting 27.89 13.74 12 42905 662 64455153
Myocardial infarction 27.82 13.74 42 42875 165779 64290036
Blood pressure decreased 27.48 13.74 122 42795 86077 64369738
Gastrointestinal scarring 27.37 13.74 9 42908 233 64455582
Hepatocellular injury 27.36 13.74 79 42838 45156 64410659
Mucosal ulceration 27.29 13.74 16 42901 1711 64454104
Therapeutic product effect prolonged 27.26 13.74 11 42906 516 64455299
Cardiac failure congestive 27.22 13.74 28 42889 130552 64325263
Gene mutation 27.01 13.74 17 42900 2065 64453750
Acute hepatic failure 26.93 13.74 56 42861 26056 64429759
Intracranial pressure increased 26.92 13.74 28 42889 6961 64448854
Herpes simplex viraemia 26.84 13.74 9 42908 248 64455567
Pneumomediastinum 26.39 13.74 19 42898 2881 64452934
Oliguria 26.39 13.74 40 42877 14536 64441279
Diabetes mellitus 26.26 13.74 6 42911 66468 64389347
Hepatitis fulminant 25.74 13.74 26 42891 6248 64449567
Pulmonary oedema 25.57 13.74 112 42805 78562 64377253
Acute kidney injury 25.47 13.74 430 42487 448810 64007005
Brain death 25.36 13.74 23 42894 4838 64450977
Intensive care unit delirium 25.20 13.74 6 42911 44 64455771
Dyspepsia 25.07 13.74 11 42906 80301 64375514
Musculoskeletal stiffness 25.03 13.74 27 42890 123179 64332636
Contraindicated product administered 24.98 13.74 21 42896 107808 64348007
Atrioventricular dissociation 24.77 13.74 9 42908 316 64455499
Large intestinal stenosis 24.57 13.74 17 42900 2420 64453395
Feeling abnormal 24.24 13.74 32 42885 133570 64322245
Blood pressure increased 24.14 13.74 49 42868 172503 64283312
Loss of personal independence in daily activities 24.12 13.74 9 42908 72445 64383370
Sedation complication 24.04 13.74 32 42885 10322 64445493
Influenza like illness 23.53 13.74 6 42911 61696 64394119
Malignant catatonia 23.47 13.74 9 42908 368 64455447
Left ventricular dysfunction 23.20 13.74 41 42876 16913 64438902
Gait disturbance 23.15 13.74 50 42867 172105 64283710
Cough 23.03 13.74 113 42804 302035 64153780
Paralysis 22.68 13.74 33 42884 11562 64444253
Product contamination 22.62 13.74 12 42905 1057 64454758
Macroglossia 22.59 13.74 12 42905 1060 64454755
Arrhythmia 22.53 13.74 82 42835 52862 64402953
Chest pain 22.47 13.74 81 42836 235899 64219916
Stomatitis 22.28 13.74 24 42893 109581 64346234
Migraine 22.23 13.74 7 42910 62670 64393145
Manipulation 22.11 13.74 6 42911 78 64455737
Rash 22.07 13.74 197 42720 458352 63997463
Mixed dementia 21.99 13.74 8 42909 282 64455533
Intensive care 21.92 13.74 10 42907 635 64455180
Pituitary apoplexy 21.71 13.74 7 42910 170 64455645
Paraesthesia 21.68 13.74 35 42882 134487 64321328
Dermatitis exfoliative generalised 21.54 13.74 23 42894 5893 64449922
Muscle spasms 21.52 13.74 38 42879 140985 64314830
Malabsorption 21.35 13.74 20 42897 4383 64451432
Amylase increased 21.07 13.74 29 42888 9656 64446159
Injection site reaction 21.05 13.74 3 42914 46661 64409154
Dry mouth 20.98 13.74 7 42910 60411 64395404
Contusion 20.98 13.74 27 42890 113938 64341877
Hospitalisation 20.92 13.74 12 42905 75195 64380620
Large intestine anastomosis 20.85 13.74 6 42911 98 64455717
Blood cholesterol increased 20.85 13.74 4 42913 50062 64405753
Haemophagocytic lymphohistiocytosis 20.84 13.74 40 42877 17569 64438246
Hot flush 20.79 13.74 3 42914 46232 64409583
Restlessness 20.79 13.74 66 42851 39719 64416096
Gastrooesophageal reflux disease 20.77 13.74 15 42902 83128 64372687
Medical device site fistula 20.73 13.74 5 42912 39 64455776
Haemoglobin decreased 20.59 13.74 64 42853 194999 64260816
Cholestasis 20.38 13.74 71 42846 44801 64411014
Hepatorenal syndrome 20.08 13.74 18 42899 3728 64452087
Drug resistance 19.98 13.74 60 42857 35042 64420773
Post procedural complication 19.96 13.74 44 42873 21309 64434506
Nervous system disorder 19.84 13.74 46 42871 23032 64432783
Pulse absent 19.78 13.74 27 42890 8919 64446896
Nail dystrophy 19.71 13.74 10 42907 803 64455012
Infection parasitic 19.61 13.74 8 42909 386 64455429
Superinfection 19.52 13.74 18 42899 3868 64451947
Nystagmus 19.50 13.74 27 42890 9041 64446774
Drug withdrawal convulsions 19.50 13.74 14 42903 2114 64453701
Completed suicide 19.45 13.74 80 42837 224334 64231481
Stupor 19.44 13.74 22 42895 6013 64449802
Liver function test 19.43 13.74 6 42911 126 64455689
Abdominal compartment syndrome 19.38 13.74 12 42905 1416 64454399
Gastrointestinal mucosa hyperaemia 19.04 13.74 8 42909 416 64455399
Brain stem auditory evoked response abnormal 18.95 13.74 3 42914 0 64455815
Euthyroid sick syndrome 18.87 13.74 5 42912 59 64455756
Cyanosis 18.87 13.74 44 42873 22111 64433704
Vomiting 18.85 13.74 256 42661 550861 63904954
Oedema peripheral 18.84 13.74 74 42843 210243 64245572
Eosinophilia 18.84 13.74 62 42855 38014 64417801
Electrocardiogram repolarisation abnormality 18.67 13.74 13 42904 1869 64453946
Symptom masked 18.62 13.74 11 42906 1193 64454622
Constipation 18.51 13.74 84 42833 229253 64226562
Drug chemical incompatibility 18.36 13.74 5 42912 66 64455749
Renal impairment 18.35 13.74 153 42764 134864 64320951
Coronary artery embolism 18.19 13.74 7 42910 289 64455526
Dyspnoea paroxysmal nocturnal 17.94 13.74 13 42904 1991 64453824
Influenza 17.85 13.74 27 42890 106504 64349311
Stridor 17.84 13.74 19 42898 4855 64450960
Impaired healing 17.77 13.74 9 42908 60464 64395351
Somnolence 17.57 13.74 210 42707 203435 64252380
Neurological examination abnormal 17.53 13.74 8 42909 508 64455307
Neutropenia 17.46 13.74 91 42826 239533 64216282
Cellulitis 17.43 13.74 22 42895 93635 64362180
Incorrect route of product administration 17.41 13.74 44 42873 23254 64432561
Injection site erythema 17.39 13.74 13 42904 70787 64385028
Nasal congestion 17.35 13.74 9 42908 59649 64396166
Cytokine release syndrome 17.34 13.74 41 42876 20788 64435027
Skin ulcer 17.31 13.74 4 42913 43970 64411845
Haematuria traumatic 17.29 13.74 6 42911 184 64455631
Transaminases increased 17.26 13.74 67 42850 44527 64411288
Delayed graft function 17.10 13.74 15 42902 3021 64452794
Alanine aminotransferase increased 17.04 13.74 154 42763 138877 64316938
Post procedural haemorrhage 16.93 13.74 30 42887 12401 64443414
Paradoxical pain 16.87 13.74 3 42914 3 64455812
Inappropriate schedule of product administration 16.84 13.74 22 42895 92264 64363551
Psychotic disorder 16.83 13.74 56 42861 34522 64421293
Burning sensation 16.82 13.74 6 42911 49658 64406157
Polyuria 16.56 13.74 30 42887 12613 64443202
Hepatitis 16.45 13.74 67 42850 45515 64410300
No adverse event 16.43 13.74 49 42868 28512 64427303
Systolic dysfunction 16.41 13.74 15 42902 3187 64452628
Myoglobin blood increased 16.33 13.74 14 42903 2733 64453082
End-tidal CO2 decreased 16.28 13.74 4 42913 34 64455781
Chronic obstructive pulmonary disease 16.25 13.74 14 42903 71034 64384781
Ischaemic hepatitis 16.23 13.74 15 42902 3231 64452584
Catecholamine crisis 16.18 13.74 4 42913 35 64455780
Post procedural stroke 16.06 13.74 5 42912 108 64455707
Cataract 16.03 13.74 7 42910 51255 64404560
Fear 16.03 13.74 39 42878 20132 64435683
Vision blurred 16.01 13.74 22 42895 90294 64365521
Hyperexplexia 15.88 13.74 4 42913 38 64455777
Injection site swelling 15.81 13.74 4 42913 41349 64414466
Injection site pruritus 15.79 13.74 3 42914 37823 64417992
Posterior reversible encephalopathy syndrome 15.78 13.74 42 42875 22904 64432911
Syncope 15.74 13.74 53 42864 157582 64298233
Areflexia 15.70 13.74 18 42899 4989 64450826
Vertigo 15.60 13.74 10 42907 59001 64396814
Transient ischaemic attack 15.55 13.74 5 42912 44177 64411638
Febrile infection-related epilepsy syndrome 15.52 13.74 4 42913 42 64455773
Local anaesthetic systemic toxicity 15.38 13.74 8 42909 677 64455138
Administration related reaction 15.33 13.74 5 42912 126 64455689
Balance disorder 15.32 13.74 20 42897 83906 64371909
Wrong product administered 15.14 13.74 22 42895 7698 64448117
Cardiac output decreased 15.13 13.74 11 42906 1693 64454122
Nephrocalcinosis 15.11 13.74 10 42907 1324 64454491
Vulvovaginal candidiasis 15.05 13.74 12 42905 2118 64453697
Endotracheal intubation complication 15.04 13.74 8 42909 708 64455107
Buttock injury 14.97 13.74 5 42912 136 64455679
Axillary pain 14.97 13.74 11 42906 1721 64454094
Osteonecrosis of jaw 14.94 13.74 4 42913 39821 64415994
Poor feeding infant 14.90 13.74 5 42912 138 64455677
Maternal exposure during pregnancy 14.85 13.74 112 42805 95772 64360043
Rash pruritic 14.80 13.74 10 42907 57394 64398421
Amaurosis 14.75 13.74 9 42908 1035 64454780
Angle closure glaucoma 14.71 13.74 13 42904 2644 64453171
Female genital tract fistula 14.70 13.74 13 42904 2645 64453170
Anaphylactoid shock 14.66 13.74 8 42909 746 64455069
Renal failure 14.65 13.74 185 42732 181503 64274312
Teratoma 14.64 13.74 5 42912 146 64455669
Gastric ulcer perforation 14.63 13.74 11 42906 1782 64454033
Sleep disorder 14.61 13.74 11 42906 59698 64396117
Exposure during pregnancy 14.54 13.74 95 42822 77580 64378235
Stevens-Johnson syndrome 14.53 13.74 53 42864 34196 64421619
Ejection fraction decreased 14.43 13.74 47 42870 28660 64427155
Mixed liver injury 14.39 13.74 18 42899 5463 64450352
Left ventricular hypertrophy 14.33 13.74 24 42893 9482 64446333
Abdominal pain 14.23 13.74 136 42781 312239 64143576
Visual impairment 14.21 13.74 17 42900 74060 64381755
Clonic convulsion 14.18 13.74 9 42908 1110 64454705
Tracheal injury 14.15 13.74 4 42913 61 64455754
Acanthosis nigricans 14.14 13.74 5 42912 162 64455653
Mobility decreased 14.14 13.74 22 42895 85818 64369997
Nephrogenic diabetes insipidus 14.13 13.74 11 42906 1876 64453939
Thrombophlebitis 13.94 13.74 18 42899 5636 64450179
Heart alternation 13.93 13.74 3 42914 13 64455802
Postoperative delirium 13.92 13.74 5 42912 170 64455645
Atrioventricular block 13.86 13.74 27 42890 11988 64443827
Ammonia increased 13.86 13.74 20 42897 6957 64448858
Sinus tachycardia 13.82 13.74 50 42867 32138 64423677
Apnoeic attack 13.78 13.74 7 42910 564 64455251
Hyperbilirubinaemia 13.76 13.74 38 42879 21167 64434648

FDA Adverse Event Reporting System (Pediatric)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Drug ineffective 53.78 30.84 27 118 890 83643
Epilepsy 31.19 30.84 10 135 90 84443

Pharmacologic Action:

SourceCodeDescription
ATC N05CD08 NERVOUS SYSTEM
PSYCHOLEPTICS
HYPNOTICS AND SEDATIVES
Benzodiazepine derivatives
FDA CS M0002356 Benzodiazepines
MeSH PA D000759 Adjuvants, Anesthesia
MeSH PA D000777 Anesthetics
MeSH PA D018686 Anesthetics, Intravenous
MeSH PA D014151 Anti-Anxiety Agents
MeSH PA D002491 Central Nervous System Agents
MeSH PA D002492 Central Nervous System Depressants
MeSH PA D018682 GABA Agents
MeSH PA D018757 GABA Modulators
MeSH PA D006993 Hypnotics and Sedatives
MeSH PA D018377 Neurotransmitter Agents
MeSH PA D011619 Psychotropic Drugs
MeSH PA D014149 Tranquilizing Agents
CHEBI has role CHEBI:35474 anti-anxiety agents
CHEBI has role CHEBI:35488 central nervous system depressants
CHEBI has role CHEBI:35610 antineoplastic agents
CHEBI has role CHEBI:35623 anticonvulsants
CHEBI has role CHEBI:35717 hypnotics
CHEBI has role CHEBI:38869 general anaesthetic
CHEBI has role CHEBI:51371 muscle relaxants
CHEBI has role CHEBI:68495 Type I cell-death inducers
CHEBI has role CHEBI:91016 GABAA receptor agonists
FDA EPC N0000175694 Benzodiazepine

Drug Use | Suggest Off label Use Form| |View source of the data|

DiseaseRelationSNOMED_IDDOID
Feeling agitated indication 24199005
Anxiety indication 48694002
General anesthesia indication 50697003
Sedation indication 72641008
Status epilepticus indication 230456007 DOID:1824
Conscious sedation indication 314271007
Local anesthesia indication 386761002
Sedation as Adjunct to Anesthesia indication
Induce Anterograde Amnesia indication
Sedation in Intubated Patients indication
Preoperative Anxiety indication
Insomnia off-label use 193462001
Cocaine-Associated Acute Ischemic Heart Disease off-label use
Chronic obstructive lung disease contraindication 13645005 DOID:3083
Cirrhosis of liver contraindication 19943007 DOID:5082
Shock contraindication 27942005
End stage renal disease contraindication 46177005 DOID:784
Chronic heart failure contraindication 48447003
Pregnancy, function contraindication 289908002
Coma contraindication 371632003
Angle-closure glaucoma contraindication 392291006 DOID:13550
Hemodynamic instability contraindication 422773005
Peripheral Vasoconstriction contraindication




๐Ÿถ Veterinary Drug Use

None

๐Ÿถ Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation levelDissociation constantType (acidic/basic)
pKa1 6.07 Basic
pKa2 2.36 Basic

Orange Book patent data (new drug applications)

Formulation strengthTrade nameApplicantApplication numberApproval dateTypeDose formRoutePatent numberPatent expiration datePatent use
5MG/SPRAY NAYZILAM UCB INC N211321 May 17, 2019 RX SPRAY NASAL 8217033 Jan. 18, 2028 ACUTE TREATMENT OF INTERMITTENT, STEREOTYPIC EPISODES OF FREQUENT SEIZURE ACTIVITY (I.E., SEIZURE CLUSTERS, ACUTE REPETITIVE SEIZURES) THAT ARE DISTINCT FROM A PATIENTS USUAL SEIZURE PATTERN IN PATIENTS WITH EPILEPSY 12 YEARS OF AGE AND OLDER
5MG/SPRAY NAYZILAM UCB INC N211321 May 17, 2019 RX SPRAY NASAL 9289432 Jan. 18, 2028 ACUTE TREATMENT OF INTERMITTENT, STEREOTYPIC EPISODES OF FREQUENT SEIZURE ACTIVITY (I.E., SEIZURE CLUSTERS, ACUTE REPETITIVE SEIZURES) THAT ARE DISTINCT FROM A PATIENTS USUAL SEIZURE PATTERN IN PATIENTS WITH EPILEPSY 12 YEARS OF AGE AND OLDER
5MG/SPRAY NAYZILAM UCB INC N211321 May 17, 2019 RX SPRAY NASAL 9687495 Jan. 18, 2028 ACUTE TREATMENT OF INTERMITTENT, STEREOTYPIC EPISODES OF FREQUENT SEIZURE ACTIVITY (I.E., SEIZURE CLUSTERS, ACUTE REPETITIVE SEIZURES) THAT ARE DISTINCT FROM A PATIENTS USUAL SEIZURE PATTERN IN PATIENTS WITH EPILEPSY 12 YEARS OF AGE AND OLDER

Orange Book exclusivity data (new drug applications)

Formulation strengthTrade nameApplicantApplication numberApproval dateTypeDose formRouteExclusivity dateDescription
5MG/SPRAY NAYZILAM UCB INC N211321 May 17, 2019 RX SPRAY NASAL May 21, 2022 NEW PRODUCT
EQ 50MG BASE/10ML (EQ 5MG BASE/ML) SEIZALAM MMT N209566 Sept. 14, 2018 RX SOLUTION INTRAMUSCULAR Sept. 14, 2025 TREATMENT OF STATUS EPILEPTICUS IN ADULTS
5MG/SPRAY NAYZILAM UCB INC N211321 May 17, 2019 RX SPRAY NASAL May 17, 2026 ACUTE TREATMENT OF INTERMITTENT, STEREOTYPIC EPISODES OF FREQUENT SEIZURE ACTIVITY (I.E., SEIZURE CLUSTERS, ACUTE REPETITIVE SEIZURES) THAT ARE DISTINCT FROM A PATIENTS USUAL SEIZURE PATTERN IN PATIENTS WITH EPILEPSY 12 YEARS OF AGE AND OLDER

Bioactivity Summary:

TargetClassPharosUniProtActionTypeActivity value
(-log[M])
Mechanism
action
Bioact sourceMoA source
GABA A receptor alpha-5/beta-2/gamma-3 Ion channel POSITIVE ALLOSTERIC MODULATOR Ki 8.26 WOMBAT-PK CHEMBL
GABA-A receptor alpha-1/beta-2/gamma-3 Ion channel POSITIVE ALLOSTERIC MODULATOR Ki 7.75 WOMBAT-PK CHEMBL
GABA A receptor alpha-3/beta-2/gamma-2 Ion channel POSITIVE ALLOSTERIC MODULATOR Ki 8.44 WOMBAT-PK CHEMBL
GABA A receptor alpha-3/beta-2/gamma-3 Ion channel POSITIVE ALLOSTERIC MODULATOR Ki 7.61 WOMBAT-PK CHEMBL
GABA A receptor alpha-5/beta-3/gamma-3 Ion channel POSITIVE ALLOSTERIC MODULATOR Ki 8.26 WOMBAT-PK CHEMBL
GABA A receptor alpha-5/beta-2/gamma-2 Ion channel POSITIVE ALLOSTERIC MODULATOR Ki 9.13 WOMBAT-PK CHEMBL
GABA-A receptor alpha-1/beta-2/gamma-2 Ion channel POSITIVE ALLOSTERIC MODULATOR Ki 8.75 WOMBAT-PK CHEMBL
GABA-A receptor alpha-5/beta-3/gamma-2 Ion channel POSITIVE ALLOSTERIC MODULATOR Ki 9.13 WOMBAT-PK CHEMBL
Multidrug resistance protein 1 Transporter Km 4.35 WOMBAT-PK
Cytochrome P450 3A4 Enzyme Km 6 WOMBAT-PK
Translocator protein Membrane receptor Ki 8.70 CHEMBL
Thyrotropin-releasing hormone receptor GPCR ANTAGONIST Ki 5.49 IUPHAR
GABA-A receptor; anion channel Ion channel Ki 8.70 CHEMBL

External reference:

IDSource
4019839 VUID
N0000147927 NUI
D00550 KEGG_DRUG
59467-96-8 SECONDARY_CAS_RN
4017813 VANDF
4019839 VANDF
C0026056 UMLSCUI
CHEBI:6931 CHEBI
08J PDB_CHEM_ID
CHEMBL655 ChEMBL_ID
CHEMBL1200420 ChEMBL_ID
DB00683 DRUGBANK_ID
D008874 MESH_DESCRIPTOR_UI
4192 PUBCHEM_CID
3342 IUPHAR_LIGAND_ID
4497 INN_ID
R60L0SM5BC UNII
203128 RXNORM
130935 MMSL
24970 MMSL
32073 MMSL
5114 MMSL
d00301 MMSL
001467 NDDF
004585 NDDF
26800000 SNOMEDCT_US
373476007 SNOMEDCT_US
84213009 SNOMEDCT_US

Pharmaceutical products:

ProductCategoryIngredientsNDCFormQuantityRouteMarketingLabel
Midazolam Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 0054-3566 SYRUP 2 mg ORAL ANDA 25 sections
Midazolam HUMAN PRESCRIPTION DRUG LABEL 1 0404-9912 INJECTION, SOLUTION 1 mg INTRAVENOUS ANDA 14 sections
Midazolam HUMAN PRESCRIPTION DRUG LABEL 1 0404-9913 INJECTION 1 mg INTRAMUSCULAR ANDA 15 sections
MIDAZOLAM HUMAN PRESCRIPTION DRUG LABEL 1 0404-9914 INJECTION, SOLUTION 5 mg INTRAVENOUS ANDA 14 sections
Midazolam HUMAN PRESCRIPTION DRUG LABEL 1 0404-9915 INJECTION, SOLUTION 5 mg INTRAVENOUS ANDA 14 sections
Midazolam Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 0404-9916 INJECTION, SOLUTION 5 mg INTRAMUSCULAR ANDA 15 sections
Midazolam Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 0409-2305 INJECTION, SOLUTION 1 mg INTRAMUSCULAR ANDA 29 sections
Midazolam Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 0409-2305 INJECTION, SOLUTION 1 mg INTRAMUSCULAR ANDA 29 sections
Midazolam Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 0409-2308 INJECTION, SOLUTION 5 mg INTRAMUSCULAR ANDA 29 sections
Midazolam Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 0409-2308 INJECTION, SOLUTION 5 mg INTRAMUSCULAR ANDA 29 sections
Midazolam Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 0409-2587 INJECTION, SOLUTION 1 mg INTRAMUSCULAR ANDA 28 sections
Midazolam Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 0409-2596 INJECTION, SOLUTION 5 mg INTRAMUSCULAR ANDA 28 sections
Midazolam Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 0574-0150 SYRUP 2 mg ORAL ANDA 27 sections
Midazolam HUMAN PRESCRIPTION DRUG LABEL 1 0641-6056 INJECTION 1 mg INTRAMUSCULAR ANDA 27 sections
Midazolam HUMAN PRESCRIPTION DRUG LABEL 1 0641-6057 INJECTION 1 mg INTRAMUSCULAR ANDA 27 sections
Midazolam HUMAN PRESCRIPTION DRUG LABEL 1 0641-6059 INJECTION 1 mg INTRAMUSCULAR ANDA 27 sections
Midazolam HUMAN PRESCRIPTION DRUG LABEL 1 0641-6060 INJECTION 5 mg INTRAMUSCULAR ANDA 27 sections
Midazolam HUMAN PRESCRIPTION DRUG LABEL 1 0641-6061 INJECTION 5 mg INTRAMUSCULAR ANDA 27 sections
Midazolam HUMAN PRESCRIPTION DRUG LABEL 1 0641-6063 INJECTION 5 mg INTRAMUSCULAR ANDA 27 sections
Midazolam HUMAN PRESCRIPTION DRUG LABEL 1 0641-6190 INJECTION 5 mg INTRAMUSCULAR ANDA 27 sections
Midazolam HUMAN PRESCRIPTION DRUG LABEL 1 0641-6190 INJECTION 5 mg INTRAMUSCULAR ANDA 27 sections
Midazolam HUMAN PRESCRIPTION DRUG LABEL 1 0641-6209 INJECTION 1 mg INTRAMUSCULAR ANDA 27 sections
Midazolam HUMAN PRESCRIPTION DRUG LABEL 1 0641-6210 INJECTION 1 mg INTRAMUSCULAR ANDA 27 sections
Midazolam HUMAN PRESCRIPTION DRUG LABEL 1 0641-6211 INJECTION 5 mg INTRAMUSCULAR ANDA 27 sections
Midazolam Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 0904-7113 SYRUP 2 mg ORAL ANDA 25 sections
Midazolam Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 0904-7114 SYRUP 2 mg ORAL ANDA 25 sections
Seizalam HUMAN PRESCRIPTION DRUG LABEL 1 11704-650 INJECTION, SOLUTION 5 mg INTRAMUSCULAR NDA 32 sections
Midazolam HUMAN PRESCRIPTION DRUG LABEL 1 17478-523 INJECTION 1 mg INTRAVENOUS ANDA 28 sections
Midazolam HUMAN PRESCRIPTION DRUG LABEL 1 17478-524 INJECTION 5 mg INTRAVENOUS ANDA 28 sections
Midazolam Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 17856-0146 SYRUP 2 mg ORAL ANDA 27 sections